Skip to main content
. 2013 Oct 17;18(11):1192–1199. doi: 10.1634/theoncologist.2012-0361

Figure 1.

Figure 1.

PFS in patients (n = 50) with metastatic or advanced gastrointestinal stromal tumor randomized to interrupt or continue imatinib therapy after 3 years of imatinib, with median follow-up of 35 months (95% CI: 33–38) after randomization [16]. Reproduced with permission from Elsevier [16].

Abbreviations: CI, confidence interval; PFS, progression-free survival.